Topical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma:

NCT07559877 · tracked via the Priya Life Science China tracker

Sponsor

Jiangxi Provincial Cancer Hospital

Phase

Phase 3

Started

2026-04-01

Last updated

2026-04-30

Condition(s) studied

Nasopharangeal Cancer

Investigational drug(s) / intervention(s)

2% chlorhexidineSterile Water as control

2% chlorhexidine: Topical 2% chlorhexidine spray

Sterile Water as control: Topical sterile water spray with identical appearance and administration schedule, plus the same standard skin care and health education.

Study summary

This study investigated the effects of topical chlorhexidine spray on the incidence, severity, and quality of life during radiotherapy in nasopharyngeal carcinoma patients.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: Histologically or cytologically confirmed nasopharyngeal carcinoma. Clinical stage II-III disease with N≥1, according to the UICC/AJCC 9th edition. Planned to receive first-course definitive chemoradiotherapy, with a total radiotherapy dose of 60-70 Gy. Able to communicate and complete study assessments. Willing to participate and able to provide written informed consent. Eligible based on baseline assessments performed before chemoradiotherapy. Exclusion Criteria: * History of or current psychiatric disorder, cognitive impairment, or other severe organic disease. Presence of another concomitant malignancy. Receipt of any other prophylactic intervention for radiation dermatitis. Pre-existing skin disease before chemoradiotherapy. Known hypersensitivity or allergy to chlorhexidine.

Primary outcome measure(s)

Grade 2 acute radiation dermatitis with moist desquamation (grade 2-MD) or higher acute radiation dermatitis — Proportion of participants who develop CTCAE v5.0 grade 2-MD or higher grade 2 ARD during radiotherapy through 1 week after radiotherapy
Incidence of Grade 2 acute radiation dermatitis with moist desquamation (grade 2-MD) or higher acute radiation dermatitis based CTCAE v5.0

Trial sites (1)

Facility	City	Region	Status
Jiangxi Cancer Hospital	Nanchang	Jiangxi	Recruiting

More Jiangxi Provincial Cancer Hospital trials in China

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients Recruiting

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast Recruiting

Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma Recruiting

Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC Recruiting

Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma Active, not recruiting

Other trials for the same condition

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma Recruiting

PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC Recruiting

PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC Recruiting

LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07559877 on ClinicalTrials.gov ↗ ← All trials in China